Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reena Philip

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Clinical Chemistry|December 17, 2009
Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnosticsHenry Rodriguez, Zivana Tezak, Mehdi Mesri, et al.
The Oncologist|October 5, 2020
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian CancerShaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2015
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Gwynn Ison, Amy E McKee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or FusionsJanice Kim, Diana Bradford, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2021
U.S. FDA Drug Approvals for Breast Cancer: A Decade in ReviewShaily Arora, Preeti Narayan, Christy L Osgood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate CancerBrian L Heiss, Elaine Chang, Xin Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2023
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA</i>-Mutated Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Jianjin Xu, Chana Weinstock, et al.
BMC Genomics|September 30, 2004
Microarrays for global expression constructed with a low redundancy set of 27,500 sequenced cDNAs representing an array of developmental stages and physiological conditions of the soybean plantLila O Vodkin, Anupama Khanna, Robin Shealy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2021
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in ReviewShaily Arora, Preeti Narayan, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Clinical Chemistry|December 17, 2009
Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnosticsHenry Rodriguez, Zivana Tezak, Mehdi Mesri, et al.
The Oncologist|October 5, 2020
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian CancerShaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2015
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Gwynn Ison, Amy E McKee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or FusionsJanice Kim, Diana Bradford, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2021
U.S. FDA Drug Approvals for Breast Cancer: A Decade in ReviewShaily Arora, Preeti Narayan, Christy L Osgood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate CancerBrian L Heiss, Elaine Chang, Xin Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2023
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA</i>-Mutated Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Jianjin Xu, Chana Weinstock, et al.
BMC Genomics|September 30, 2004
Microarrays for global expression constructed with a low redundancy set of 27,500 sequenced cDNAs representing an array of developmental stages and physiological conditions of the soybean plantLila O Vodkin, Anupama Khanna, Robin Shealy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2021
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in ReviewShaily Arora, Preeti Narayan, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
Pageof 6